AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32066609
Drug: Additional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional treatment
Trial: 33180097
Drug: Fluvoxamine 100
RxNorm normalized name: fluvoxamine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 100 mg, 3 times daily for 15 days
Trial: 33180097
Drug: Placebo, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3 times daily for 15 days
Trial: 32116248
Drug: Learning Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Learning Therapy (LT), a combination of cognitive training and stimulation
Trial: 32700396
Drug: Cilostazol 200
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 200 mg/d
Trial: 32506275
Drug: Preoperative meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative meloxicam 15 mg at 24 h pre-operation, 7.5 mg at 4 h, 24 h, 48 h and 72 h post-operation
Trial: 32506275
Drug: Postoperative meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative meloxicam 15 mg at 4 h post-operation, then 7.5 mg at 24 h, 48 h and 72 h post-operation
Trial: 33285743
Drug: Afatinib monotherapy
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib monotherapy (20-40 mg)
Trial: 33285743
Drug: Afatinib plus
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib plus HAD-B1 combination therapy (0.972 g/day for 48 weeks)
Trial: 33850467
Drug: Multidisciplinary treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary treatment
Trial: 32544356
Drug: No pre‐treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pre‐treatment (Group 3, n=12)
Trial: 32390113
Drug: Upfront autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront autologous hematopoietic stem cell transplantation (ASCT) following rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy
Trial: 34818873
Drug: BT200 (0.18-48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BT200 (0.18-48 mg) subcutaneously
Trial: 35238750
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg pegloticase every 2 weeks (q2w)
Trial: 35238750
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg pegloticase every 4 weeks (q4w)
Trial: 36856614
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg once daily
Trial: 34613954
Drug: Gluten challenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten challenges (0, 10, 50, 100, 500, and 1,000 mg) during study A
Trial: 34613954
Drug: Gluten challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gluten challenge with 5 or 10 mg gluten during study B
Trial: 32543258
Drug: Immediate maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate maintenance pemetrexed therapy
Trial: 33225965
Drug: Anakinra (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (300 mg daily)
Trial: 36233636
Drug: Denneroll cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denneroll cervical traction orthotic + TENS therapy + hot packs
Trial: 36233636
Drug: TENS therapy
RxNorm normalized name: Walgreens Electronic TENS Therapy Pain Relief Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TENS therapy + hot packs
Trial: 34836149
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (GTE; containing 500 mg epigallocatechin-3-gallate)
Trial: 34117622
Drug: Early total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early total enteral nutrition (80 mL/kg/d starting on day 1, advanced by 20 mL/kg/d)
Trial: 34117622
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (30 mL/kg/d starting on day 1, advanced by 20 mL/kg/d)
Trial: 38754459
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg daily for 6 weeks
Trial: 35871814
Drug: Abrocitinib 200
RxNorm normalized name: abrocitinib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrocitinib 200 mg per day
Trial: 32150215
Drug: 6-month structured
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month structured physical activity with or without a protein and vitamin D nutritional supplement
Trial: 35619221
Drug: Melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin treatment (10 mg)
Trial: 34424558
Drug: Treatment shampoo
RxNorm normalized name: Lice Treatment Shampoo Max
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment shampoo and leave‐on treatment containing functional antioxidants and barrier‐enhancing agents
Trial: 32334176
Drug: Clinically indicated
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically indicated replacement group (removal only at end of therapy or in presence of complications)
Trial: 32590482
Drug: Bromfenac ophthalmic
RxNorm normalized name: bromfenac ophthalmic
DrugBank: Bromfenac (DB00963)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromfenac ophthalmic solution 0.09% prescribed 3 times a day for 1 month
Trial: 32590482
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate 1% eye suspension prescribed 4 times a day for 1 month
Trial: 33557898
Drug: Shi-style cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shi-style cervical manipulation therapy
Trial: 33557898
Drug: NSAIDs (traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (traditional analgesic drug)
Trial: 32655854
Drug: High-dose scopolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose scopolamine
Trial: 33331082
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg IV every 4 weeks; 6 doses)
Trial: 33370867
Drug: Oseltamivir phosphate
RxNorm normalized name: Oseltamivir Phosphate
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oseltamivir phosphate capsule, 75 mg each time, twice a day for 5 days
Trial: 32382987
Drug: Sequencing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequencing of novel agents based on RWE data
Trial: 33412120
Drug: Nintedanib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (150 mg orally twice daily)
Trial: 34091874
Drug: Citicoline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline and vitamin B12 eye drops (OMK2®, Omikron Italia srl, Italy, one drop thrice daily) for 36 months
Trial: 34091874
Drug: Placebo (eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (eye drops containing hypromellose 0.3%, one drop thrice daily) for 36 months
Trial: 34960030
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg PXN + 150 mg PLA
Trial: 34960030
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg PXN + 100 mg PLA
Trial: 34960030
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg PXN
Trial: 34960030
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg PLA
Trial: 36104785
Drug: Nebulised unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised unfractionated heparin 6 hourly to day 10 while receiving advanced respiratory support
Trial: 32727416
Drug: Transoral surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transoral surgical resection with neck dissection followed by risk-adapted adjuvant therapy
Trial: 35675742
Drug: Bee-humming respiratory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bee-humming respiratory training (BHRT), 30 minutes daily for 4 weeks
Trial: 33650100
Drug: Carfilzomib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib (20 mg/m2 on day 1, escalating to 56 mg/m2 maximum) with dexamethasone (10 mg as premedication) during maintenance
Trial: 33650100
Drug: Maintenance single-agent
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance single-agent carfilzomib
Trial: 34369682
Drug: Electroacupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture combined with ultrasound guided caudal epidural injection
Trial: 34369682
Drug: Ultrasound guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided caudal epidural injection
Trial: 33566077
Drug: Regular oral
RxNorm normalized name: infant formula,regular ORAL PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular oral hygiene (Control group)
Trial: 35634694
Drug: Lemborexant 10
RxNorm normalized name: lemborexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant 10 mg plus alcohol (males, 0.7 g/kg; females, 0.6 g/kg)
Trial: 35634694
Drug: Lemborexant 10
RxNorm normalized name: lemborexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant 10 mg alone
Trial: 35634694
Drug: Lemborexant 10
RxNorm normalized name: lemborexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant 10 mg plus alcohol
Trial: 35634694
Drug: Lemborexant 10
RxNorm normalized name: lemborexant 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant 10 mg alone or with alcohol
Trial: 33185932
Drug: Low-dose isotretinoin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isotretinoin (0.25 mg/kg/day) and five sessions of pulsed dye laser (PDL)
Trial: 33185932
Drug: Standard-dose isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard-dose isotretinoin (0.5 mg/kg/day)
Trial: 33185932
Drug: ISO group
RxNorm normalized name: iso-sulfan blue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISO group (0.5 mg/kg/day)
Trial: 33185932
Drug: ISO/PDL group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISO/PDL group (0.25 mg/kg/day + PDL)
Trial: 35879941
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg GBP510 adjuvanted with AS03 (Group 1)
Trial: 35879941
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg unadjuvanted GBP510 (Group 2)
Trial: 35879941
Drug: 25 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 µg GBP510 adjuvanted with AS03 (Group 3)
Trial: 35879941
Drug: 25 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 µg unadjuvanted GBP510 (Group 4)
Trial: 35879941
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg or 25 µg GBP510 adjuvanted with AS03
Trial: 34001223
Drug: Credelio Plus
RxNorm normalized name: Credelio
DrugBank: Lotilaner (DB17992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Credelio Plus tablets (milbemycin oxime + lotilaner)
Trial: 34001223
Drug: Nexgard Spectra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nexgard Spectra® tablets (control product)
Trial: 34001223
Drug: Credelio Plus
RxNorm normalized name: Credelio
DrugBank: Lotilaner (DB17992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Credelio Plus tablets
Trial: 32936874
Drug: Immunonutrient supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunonutrient supplement (3 sachets/d) enriched with l-arginine and omega-3 fatty acids
Trial: 36188425
Drug: Panax notoginseng
RxNorm normalized name: PANAX NOTOGINSENG TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panax notoginseng Ejiao suppository
Trial: 36188425
Drug: mesalazine suppository
RxNorm normalized name: mesalamine Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mesalazine suppository
Trial: 33146324
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment in primary health care
Trial: 35787809
Drug: Chamomile oil
RxNorm normalized name: chamomile oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile oil (1.5 cc applied to lumbar region, three times a day for three weeks)
Trial: 33500355
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) combined with orteronel
Trial: 33500355
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) combined with bicalutamide
Trial: 33409919
Drug: Probiotic and
RxNorm normalized name: Florastor Advanced Probiotic And Digestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic and selenium co-supplementation (8 × 10^9 CFU/day probiotic plus 200 μg/day selenium)
Trial: 35444528
Drug: Non-preparation group
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-preparation group
Trial: 32678530
Drug: Dexamethasone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (6 mg once daily for up to 10 days)
Trial: 33399309
Drug: Second-line HIV
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-line HIV therapy
Trial: 33065768
Drug: Medical cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical cannabis treatment
Trial: 32967912
Drug: Sipuleucel-T (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sipuleucel-T (administered as three infusions)
Trial: 32967912
Drug: Sipuleucel-T (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sipuleucel-T (first infusion)
Trial: 36258655
Drug: Presented Centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presented Centered Therapy (PCT)
Trial: 34533246
Drug: Myrtle fruit
RxNorm normalized name: Myrtle blueberry fruit
DrugBank: Bilberry (DB14235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myrtle fruit syrup with omeprazole
Trial: 34533246
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup with omeprazole
Trial: 35257230
Drug: Acupressure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupressure therapy (8-min acupressure from Zhongwan (CV12), Guanyuan (CV4), and Tianshu (ST25) acupoints once a day for 4 weeks)
Trial: 34085769
Drug: YH12852 (0.05-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH12852 (0.05-5 mg)
Trial: 34085769
Drug: YH12852 (0.05-0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH12852 (0.05-0.1 mg)
Trial: 34085769
Drug: YH12852 (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH12852 (doses >0.1 mg extrapolated)
Trial: 38869899
Drug: Emotional Awareness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotional Awareness and Expression Therapy (EAET)
Trial: 37441660
Drug: Oral glibenclamide
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral glibenclamide
Trial: 33405051
Drug: G. lucidum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G. lucidum treatment
Trial: 33256419
Drug: Pylera® (quadruple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pylera® (quadruple therapy)
Trial: 33256419
Drug: AST-guided triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-guided triple therapy
Trial: 33256419
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Pylera® and AST-guided triple therapy)
Trial: 32719981
Drug: Eldecalcitol (ELD)
RxNorm normalized name: Decalcitrol
DrugBank: Eldecalcitol (DB05295)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Eldecalcitol (ELD) 0.75 μg once-a-day for 24 weeks
Trial: 32719981
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) 35 mg once-a-week for 24 weeks
Trial: 33788465
Drug: Wei's triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wei's triple nine needling combined with conventional medication
Trial: 33222703
Drug: Inactive control
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive control therapy (befriending)
Trial: 34144176
Drug: Single-dose HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose HPV vaccination
Trial: 34144176
Drug: Two-dose HPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose HPV vaccination
Trial: 35267477
Drug: Ramucirumab monotherapy
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab monotherapy at 8 mg/kg Q2W
Trial: 35267477
Drug: Ramucirumab monotherapy
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab monotherapy at 12 mg/kg Q2W
Trial: 35267477
Drug: Ramucirumab monotherapy
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab monotherapy at 6 mg/kg QW
Trial: 35267477
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2-D1D8D15) plus ramucirumab (12 mg/kg-Q2W)
Trial: 35267477
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2-D1D8D15) plus ramucirumab (8 mg/kg-Q2W)
Trial: 33433318
Drug: Ferumoxytol 510
RxNorm normalized name: ferumoxytol 510 mg/17 mL (30 mg/mL) INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferumoxytol 510 mg once or twice quarterly
Trial: 33433318
Drug: Sodium ferric
RxNorm normalized name: Sodium ferric EDTA
DrugBank: Sodium feredetate (DB13381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium ferric gluconate 125 mg weekly
Trial: 32151220
Drug: GIK (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK (200 g/L glucose, 66.7 U/L insulin, and 80 mmol/L KCl) administered intravenously at 1 mL/kg per hour 10 minutes before anesthesia and continuously for 12.5 hours
Trial: 34177805
Drug: Yoga-based lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga-based lifestyle modification protocol (YLP) for 9 consecutive days, followed by daily home and weekly supervised practices for 3 months.
Trial: 32715401
Drug: TXA (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA (intravenous tranexamic acid)
Trial: 35130487
Drug: Multi-dose priming
RxNorm normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dose priming regimen (days 1, 8, and 29) with 9 × 10^5 PfSPZ/dose
Trial: 35130487
Drug: Multi-dose priming
RxNorm normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dose priming regimens (days 1, 3, 5, 7, and 113; days 1, 3, 5, and 7; days 1, 3, 5, 7, and 29)
Trial: 35076087
Drug: Naltrexone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (2 pills)
Trial: 35076087
Drug: Naltrexone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (1 pill)
Trial: 35568049
Drug: WEVEE VLP
RxNorm normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WEVEE VLP vaccine (6 μg, 30 μg, or 60 μg) with or without aluminium hydroxide suspension (alum) adjuvant, administered by intramuscular injection at study day 0 and week 8.
Trial: 35568049
Drug: 30 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 μg plus alum group
Trial: 35568049
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of WEVEE VLP vaccine
Trial: 34839481
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (1,000 mg dose of low-molecular weight iron dextran over one hour)
Trial: 34839481
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (IV iron and oral iron)
Trial: 32200827
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (topical prednisolone phosphate)
Trial: 32421159
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (EVT) with standard medical care
Trial: 32275032
Drug: Morphine 20
RxNorm normalized name: morphine 20 mg/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 20 mg
Trial: 36079884
Drug: 6AA (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6AA (12 g of non‐essential amino acid formulation orally, 4 g three times a day)
Trial: 36079884
Drug: Placebo (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equivalent doses to 6AA)
Trial: 33452595
Drug: Exenatide (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (twice daily for 16 weeks)